Juvaris reports strong Ph I trial flu vaccine adjuvant

Juvaris BioTherapeutics, a US biotechnology company developing adjuvanted vaccines and immunotherapeutics for infectious diseases and  cancer, has reported positive results from a Phase I trial of its lead  compound, JVRS-100, as an adjuvant for influenza vaccines.

Results from the randomized, double-blind, controlled trial demonstrated  positive effects of the JVRS-100 adjuvant co-administered with a  commercial influenza vaccine compared to vaccine alone. Increased  antibody responses measured by serum hemagglutination inhibition and  neutralizing antibody titers were observed in subjects receiving  JVRS-100 and vaccine versus vaccine alone in study participants 28 days  post-vaccination.

HAI and neutralization titers are the accepted correlates of increased  protection against illness after exposure to influenza. JVRS-100  administered at the most efficacious dose was well tolerated, with no  additional side effects over those associated with influenza vaccine  alone. The trial enrolled 128 healthy adult subjects 18 to 49 years of  age.